secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001437749-26-006233
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen reports FY2025 net loss $153.5M; ZUSDURI launch net sales $15.8M; refinances debt at 8.25%
--------------------------------------------------------------------------------

- FY2025 revenue $109.8M (+21% YoY); JELMYTO net sales $94M (underlying demand +7%).
- ZUSDURI net sales $15.8M in initial launch; 838 activated sites, 102 unique prescribers as of Dec 31, 2025.
- Permanent J Code (J9282) effective Jan 1, 2026; launch acceleration expected.
- Refinanced existing term loan: $200M funded at 8.25% fixed, new $50M tranche available until June 2027.
- 2026 guidance: JELMYTO net sales $97-101M; total operating expenses $240-250M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/0001437749-26-006233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/urgn20260226_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-006233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer